{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:23:36Z","timestamp":1793683416368,"version":"4.5.1"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T00:00:00Z","timestamp":1313452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Intensive chemotherapy regimens are not feasible in many adults with mantle cell lymphoma (MCL). We sought to build upon our previous experience with a non\u2010intensive regimen, modified R\u2010hyperCVAD chemotherapy (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) with maintenance rituximab (MR), by the incorporation of bortezomib (VcR\u2010CVAD) and the extension of MR beyond 2\u2003years. Patients with previously untreated MCL received VcR\u2010CVAD chemotherapy every 21\u2003d for six cycles. Patients achieving at least a partial response to induction chemotherapy received rituximab consolidation (375\u2003mg\/m<jats:sup>2<\/jats:sup>\u2003\u00d7\u20034\u2003weekly doses) and MR (375\u2003mg\/m<jats:sup>2<\/jats:sup> every 12\u2003weeks\u2003\u00d7\u200320 doses). The primary end points were overall and complete response (CR), and secondary endpoints were progression\u2010free (PFS) and overall survival (OS). Thirty patients were enrolled, with a median age of 61\u2003years. All patients had advanced stage disease, and 60% had medium\/high MCL International Prognostic Index risk factors. A CR or unconfirmed CR was achieved in 77% of patients. After a median follow\u2010up of 42\u2003months, the 3\u2010year PFS and OS were 63% and 86%, respectively. The observed 3\u2010year PFS and OS with VcR\u2010CVAD in MCL were comparable to reported outcomes with more intensive regimens. A cooperative group trial (E1405) is attempting to replicate these promising results.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08820.x","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T15:18:23Z","timestamp":1313507903000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["VcR\u2010CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study"],"prefix":"10.1111","volume":"155","author":[{"given":"Julie E.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangbum","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae E.","family":"Werndli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Huie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter L.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"e_1_2_9_4_1","first-page":"581","article-title":"RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA","volume":"112","author":"Delarue R.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"e_1_2_9_6_1","first-page":"285","article-title":"Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantion in first remission of mantle cell lymphoma","volume":"112","author":"Dreyling M.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.s.034"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25509"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/jco.2004.22.90140.6502","article-title":"Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract 6502]","volume":"22","author":"Hochster H.S.","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl127"},{"key":"e_1_2_9_19_1","article-title":"The VcR\u2010CVAD regimen produces a high complete response rate in untreated Mantle Cell Lymphoma (MCL): first analysis of E1405 \u2013 A phase II study of VcR\u2010CVAD with maintenance rituximab for MCL","volume":"114","author":"Kahl B.S.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn045"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"e_1_2_9_23_1","unstructured":"National Cancer Institute. (2006)Common terminology criteria for adverse events v3.0. Available at:http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf."},{"key":"e_1_2_9_24_1","unstructured":"National Comprehensive Cancer Network(2008)NCCN clinical practice guidelines in oncology. Non\u2010Hodgkin\u2019s lymphomas. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp v3."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200620010-00002"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non\u2010Hodgkin\u2019s lymphoma. The Non\u2010Hodgkin\u2019s Lymphoma Classification Project","volume":"89","author":"The Non\u2010Hodgkin\u2019s Lymphoma Classification Project.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774507084102"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08820.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08820.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:47:20Z","timestamp":1697417240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08820.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,16]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08820.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08820.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,16]]},"assertion":[{"value":"2011-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}